스타틴 치료, CK, AST/ALT 측정, LDL-C 모니터링

일상적인 CK 수치 측정을 권고하지 않습니다. 그러나 스타틴 시작이전에 참고 목적으로 기저 수치를 얻는 것은 유용합니다.

스타틴 치료 이전에 AST/ALT 기저 수치를 측정합니다. 그러나 일상적으로 AST/ALT 수치를 측정하지는 않습니다.

Routine monitoring of serum creatine kinase (CK) levels is not recommended in patients on statins, but it is useful to obtain a baseline CK level for reference purposes prior to starting statin therapy. Patients treated with statins should be alerted to report the new onset of myalgias or weakness. 

We check baseline aminotransferase levels prior to initiating statin therapy; we do not routinely monitor these levels in patients on statins.

스타틴 치료 후 6주 후에 LCL-C 수치를 측정하고 이후에는 6개월-1년마다 측정하는 것이 약물 복용과 식이를 평가하는데 도움이 됩니다.

There are no reliable data on the optimal method of monitoring the effects of lipid-lowering therapy. We suggest that the LDL-C be monitored approximately six weeks after the initiation or change of treatment. If LDL reduction is substantially less than expected, possible nontolerance or nonadherence to treatment should be carefully explored. Thereafter, measurement every 6 to 12 months is reasonable in patients adherent to lifestyle modifications to examine for continued adherence and increasing LDL levels with aging.

With statins in particular, lipid levels stabilize within several weeks after a change in dose, and so checking lipid levels six weeks after a dosage change should provide a reliable result. As discussed elsewhere, however, the beneficial effects of statins appear to occur sooner than can be explained by changes in LDL-C, and with discontinuation may reverse more quickly as well.

REF. UpToDate 2018.04.19

---